Expression of erythropoietin and its receptor in neuroblastomas

Cancer

Volumn 110, Issue 5, 2007, Pages 1096-1106

  Sartelet, Hervé ^a   Fabre, Monique ^b   Castaing, Marine ^c   Bosq, Jacques ^c   Racu, Ivan ^c   Lagonotte, Emeryc ^d   Scott, Véronique ^c   Lecluse, Yann ^c   Barette, Stephane ^a   Michiels, Stefan ^c   Vassal, Gilles ^c  

^a UNIVERSITY OF MONTREAL   (Canada)

^b BICÊTRE HOSPITAL   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d REIMS UNIVERSITY HOSPITAL   (France)

Author keywords

Cell culture; Erythropoietin; Erythropoietin receptor; Neuroblastoma; Tissue microarray

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; RECOMBINANT ERYTHROPOIETIN;

ANTIBODY DETECTION; ARTICLE; CANCER RISK; CELL PROLIFERATION; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; DRUG SAFETY; ERYTHROPOIESIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INFANT; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; NEUROBLASTOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SCORING SYSTEM; TISSUE MICROARRAY;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; INFANT, NEWBORN; KAPLAN-MEIERS ESTIMATE; MALE; NEOPLASM STAGING; NEUROBLASTOMA; RECEPTORS, ERYTHROPOIETIN;

EID: 34548161623     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22879     Document Type: Article

References (48)

1. Krantz SB. Erythropoietin. Blood. 1991;77:419-434.
2. Ebert BL, Bunn HF. Regulation of the erythropoietin gene. Blood. 1999;94:1864-1877.
3. Lappin T. The cellular biology of erythropoietin receptors. Oncologist. 2003;8:15-18.
4. Mulcahy L. The erythropoietin receptor. Semin Oncol. 2001;2:19-23.
5. Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP, Dewhirst MW. Erythropoietin biology in cancer. Clin Cancer Res. 2006;12:332-339.
6. Nagai A, Nakagawa E, Choi HB, et al. Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol. 2001;60:386-392.
7. Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci. 2005;6: 484-494.
8. Knabe W, Knerlich F, Washausen S, et al. Expression patterns of erythropoietin and its receptor in the developing midbrain. Anat Embryol (Berl). 2004;207:503-512.
9. Koshimura K, Murakami Y, Sohmiya M, Tanaka J, Kato Y. Effects of erythropoietin on neuronal activity. J Neurochem. 1999;72:2565-2572.
10. Acs G, Acs P, Beckwith SM, et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res. 2001;61:3561-3565.
11. Acs G, Zhang PJ, McGrath CM, et al. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol. 2003;162:1789-1806.
12. Yasuda Y, Fujita Y, Masuda S, et al. Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproductive organs. Carcinogenesis. 2002;23: 1797-1805.
13. Kumar SM, Acs G, Fang D, et al. Functional erythropoietin autocrine loop in melanoma. Am J Pathol. 2005;166:823-830.
14. Yasuda Y, Musha T, Tanaka H, et al. Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice. Br J Cancer. 2001;84:836-843.
15. Acs G, Xu X, Chu C, et al. Prognostic significance of erythropoietin expression in human endometrial carcinoma. Cancer. 2004;100:2376-2386.
16. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003;362:1255-1260.
17. Westphal G, Niederberger E, Blum C, et al. Erythropoietin and G-CSF receptors in human tumor cells: expression and aspects regarding functionality. Tumori. 2002;88:150-159.
18. Lai SY, Grandis JR. Understanding the presence and function of erythropoietin receptors on cancer cells. J Clin Oncol. 2006;24:4675-4676.
19. Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol. 2001;19:2875-2882.
20. Powles T, Shamash J, Liu W. Erythropoietin to treat anaemia in patients with head and neck cancer [comment]. Lancet. 2004;363:82.
21. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003;3:203-216.
22. Schmidt ML, Lukens JN, Seeger RC, et al. Biologic factors determine prognosis in infants with stage IV neuroblastoma: a prospective Children's Cancer Group study. J Clin Oncol. 2000;18:1260-1268.
23. Batra S, Perelman N, Luck LR, et al. Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest. 2003;83:1477-1487.
24. Rossler J, Stolze I, Frede S, et al. Hypoxia-induced erythropoietin expression in human neuroblastoma requires a methylation free HIF-1 binding site. J Cell Biochem. 2004;93:153-161.
25. Stolze I, Berchner-Pfannschmidt U, Freitag P, et al. Hypoxia-inducible erythropoietin gene expression in human neuroblastoma cells. Blood. 2002;100:2623-2628.
26. Assandri R, Egger M, Gassmann M, et al. Erythropoietin modulates intracellular calcium in a human neuroblastoma cell line. J Physiol. 1999;516:343-352.
27. Brodeur GM, Seeger RC, Barrett A, et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol. 1988;6:1874-1881.
28. Shimada H, Ambros IM, Dehner LP, et al. Terminology and morphologic criteria of neuroblastic tumors. Cancer. 1999;86:349-363.
29. Hoos A, Urist MJ, Stojadinovic A, et al. Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol. 2001;158:1245-1251.
30. Vassal G, Terrier-Lacombe MJ, Bissery MC, et al. Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts. Br J Cancer. 1996;74:537-545.
31. Ferrandis E, Da Silva J, Riou G, Benard I. Coactivation of the MDR1 and MYCN genes in human neuroblastoma cells during the metastatic process in the nude mouse. Cancer Res. 1994;54:2256-2261.
32. Conrad KP, Benyo DF, Westerhausen-Larsen A, Miles TM. Expression of erythropoietin by the human placenta. FASEB J. 1996;10:760-768.
33. Ehlers RA, Kim S, Zhang Y, et al. Gut peptide receptor expression in human pancreatic cancers. Ann Surg. 2000;231:838-848.
34. Jilani S, Glaspy JA. Impact of epoetin alfa in chemotherapy-associated anemia. Semin Oncol. 1998;25:571-576.
35. Hockenberry MJ, Hinds PS, Barrera P, et al. Incidence of anemia in children with solid tumors or Hodgkin disease. J Pediatr Hematol Oncol. 2002;24:35-37.
36. Leon P, Jimenez M, Barona P, Sierrasesumaga L. Recombinant human erythropoietin for the treatment of anemia in children with solid malignant tumors. Med Pediatr Oncol. 1998;30:110-116.
37. Varan A, Buyukpamukcu M, Kutluk T, Akyuz C. Recombinant human erythropoietin treatment for chemotherapy-related anemia in children. Pediatrics. 1999;103:E16-E16.
38. Buyukpamukcu M, Varan A, Kutluk T, Akyuz C. Is epoetin alfa a treatment option for chemotherapy-related anemia in children? Med Pediatr Oncol. 2002;39:455-458.
39. Zoubek A, Kronberger M. Early epoetin alfa treatment in children with solid tumors. Med Pediatr Oncol. 2002;39: 459-462.
40. Razzouk BI, Hord JD, Hockenberry M, et al. Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy. J Clin Oncol. 2006;24:3583-3589.
41. Wagner LM, Billups CA, Furman WL, et al. Combined use of erythropoietin and granulocyte colony-stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: a randomized controlled trial. J Clin Oncol. 2004;22:1886-1893.
42. Dagnon K, Pacary E, Commo F, et al. Expression of erythropoietin and erythropoietin receptor in non-small cell lung carcinomas. Clin Cancer Res. 2005;11:993-999.
43. Konishi Y, Chui DH, Hirose H, Kunishita T, Tabira T. Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo. Brain Res. 1993;609:29-35.
44. Wollman Y, Westphal G, Blum M, et al. The effect of human recombinant erythropoietin on the growth of a human neuroblastoma cell line. Life Sci. 1996;59:315-322.
45. Wiesener MS, Seyfarth M, Warnecke C, et al. Paraneoplastic erythrocytosis associated with an inactivating point mutation of the von Hippel-Lindau gene in a renal cell carcinoma. Blood. 2002;99:3562-3565.
46. Wood L, Swanepoel C, du Toit A, Jacobs P. Clinically silent renal tumour producing erythropoietin. S Afr Med J. 2003; 93:128-129.
47. Murphy JK, Hunt KM. Polycythaemia and neuroblastoma. Ir J Med Sci. 1991;160:114-115.
48. Wang LY, Shih LY, Chen SH, et al. Neuroblastoma with expression of erythropoietin resulting in erythrocytosis. J Pediatr Hematol Oncol. 2003;25:649-650.